Genmab A/S (FRA:GE91)

Market Cap	15.29B +29.3%
Revenue (ttm)	3.17B +19.2%
Net Income	820.19M -15.0%
EPS	13.09 -12.3%
Shares Out	n/a
PE Ratio	18.64
Forward PE	21.44
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	0
Open	24.20
Previous Close	24.40
Day's Range	24.20 - 24.20
52-Week Range	15.90 - 29.80
Beta	n/a
RSI	31.93
Earnings Date	Feb 17, 2026

About Genmab

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell n...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1998
• Employees: 3,029
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: GE91

Financial Performance

In 2025, Genmab's revenue was $3.72 billion, an increase of 19.19% compared to the previous year's $3.12 billion. Earnings were $963.00 million, a decrease of -15.00%.

Financial numbers in USD